FDA - Spark Newswire

2 minute read

FDA
News

Summit Therapeutics Highlights Presentation Of Research Updates At Annual European Congress of Clinical Microbiology & Infectious Diseases Conference Jul. 9-12

Today, 6:48 PM

Summit Therapeutics Inc. (NASDAQ:SMMT) (the “Company”) today announced that members of our scientific team will present breakthrough research updates at the 31st European Congress of Clinical Microbiology

SMMT

3 minute read

FDA
News

Celsion Reports Commencement Of Enrollment In Oxford University’s Phase 1 Study With Its ThermoDox, Focused Ultrasound In Pancreatic Cancer

By Benzinga Newsdesk

Today, 6:48 PM

Celsion Corporation (NASDAQ:CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company, announces commencement of enrollment in Oxford University’s Phase I PanDox

CLSN

2 minute read

FDA
News

Achilles Therapeutics Reports Enrollment Of First US Patient In Ongoing Phase 1/2a Study In Advanced Non-Small Cell Lung Cancer

By Benzinga Newsdesk

Today, 6:48 PM

- Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator - - CHIRON trial is enrolling up to 40 patients with advanced unresectable or metastatic non-small cell lung

ACHL

3 minute read

FDA
News

I-Mab Announces Multiple Advancements Of 4-1BB Bispecific Antibody Portfolio

By Benzinga Newsdesk

Today, 6:48 PM

I-Mab (the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced multiple advancements in its

IMAB

1 minute read

FDA
News

AstraZeneca Reports Results For Its Investigational Myeloperoxidase Inhibitor In Heart Failure, Showed 69% Reduction In Myeloperoxidase Activity In AZD4831 Group From Baseline To Day 30

By Benzinga Newsdesk

Today, 6:48 PM

-Reuters

AZN

1 minute read

Mesoblast Updates On Rexlemestrocel-L Program In Chronic Low Back Pain

By Vandana Singh

Today, 6:48 PM

Mesoblast Limited (NASDAQ:MESO) provided an update on the strategy for bringing rexlemestrocel-L to patients in the U.S. with chronic low back…

MESO

3 minute read

Novocure Highlights Presentation Of Final Safety And Efficacy Results From Phase 2 Pilot HEPANOVA Trial In Liver Cancer; Disease Control Rate With 76% With 9.5% Objective Response Rate

By Bill Haddad

Today, 6:48 PM

Disease control rate was 76% with 9.5% objective response in a patient population with poor prognosis and limited exposure to study treatments In patients who completed at least 12 weeks of Tumor

NVCR

3 minute read

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement; Seres To Receive $175M Upfront Payment And Additional $125M Upon FDA Approval Of SER-109

By Bill Haddad

Today, 6:48 PM

Companies Agree to Jointly Commercialize SER-109 Investigational Microbiome Therapeutic to Treat Recurrent C. difficile Infection, Leading the Way for Entirely New Treatment Modality Deal calls for more

MCRB

4 minute read

FDA
News

Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer’s Disease

By Benzinga Newsdesk

Today, 6:48 PM

Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company (the "Company"), announced today that Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a preclinical stage

ALZN

1 minute read

Jazz Pharma’s Rylaze Scores FDA Approval For Blood Cancer

By Vandana Singh

Today, 6:48 PM

The FDA has approved Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the treatment of acute lymphoblastic leukemia or…

JAZZ